Zacks Investment Research on MSN
CRMD up more than 40% YTD: Time to buy, sell or hold the stock?
Shares of CorMedix CRMD have witnessed a strong surge so far this year, primarily driven by the continued strong uptake of ...
Zacks Investment Research on MSN
Can DefenCath continue to aid CorMedix's long-term growth ahead?
CorMedix’s CRMD lead therapy, DefenCath (taurolidine + heparin), is currently the company’s majority revenue driver. The FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback